NEW YORK (GenomeWeb News) – Shares of Exact Sciences today fell as much as 30 percent after the company announced top-line data from a pivotal clinical trial for its colorectal cancer screening test.

Amid heavy trading, shares of the Madison, Wis.-based firm dipped to as low as $6.93 from Wednesday's closing price of $9.97, after results from the trial, called DeeP-C, failed to meet some internal targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.